Le MK-7684A, avec ou sans autres traitements anticancéreux, chez des participants atteints de certaines tumeurs solides
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors.